Consolidated revenue for the quarter increased by 91.1% YoY (-2.9% QoQ) to INR 4,858 Mn., stood sharply above our estimates, led by rapid ramp-up of pharma molecule, strong rebound in agrochemicals, commercialization of polymer products, new global contracts, and higher export revenue mix.
OutlookWe have rolled forward our valuation to Jun’27 estimates. We value Anupam Rasayan at 45.0x Jun’27 EPS (near to its 3-year Avg. NTM P/E"), implying a target price of INR 1,230. We reiterate our “ACCUMULATE” rating on the stock.
For all recommendations report, click hereDisclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Anupam Rasayan India - 22082025 - khanDiscover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
